Recent Updates
Recently added Catalysts
ALT Negative Sentiment Score: 20/100

Altimmune, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT

Key Takeaway: Altimmune, Inc. is facing a class action lawsuit for securities law violations following disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide. The trial results, published on June 26, 2025, indicated a failure to achieve statistical significance in the primary endpoint of fibrosis reduction, despite earlier optimistic projections from the company. This led to a dramatic stock price drop from $7.71 to $3.61 per share within a day. Shareholders are being encouraged to register for the class action, which has a deadline of October 6, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Altimmune's stock price plummeted by 53.2% in one day after they failed to meet statistical significance in a crucial clinical trial.
  • The company has been accused of providing inflated expectations regarding the trial results.
  • The failure to achieve statistically significant results could impact investor confidence and future funding.
  • Legal action from shareholders indicates significant dissatisfaction with the company's management and communication.

Full Press Release Details

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 10, 2023 to June 25, 2025
ALLEGATIONS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.
DEADLINE: October 6, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=165013&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 6, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Altimmune shareholders?

The class period for Altimmune shareholders is from August 10, 2023, to June 25, 2025.

What did Altimmune report on June 26, 2025?

On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial.

What caused Altimmune's stock price to decline?

The stock price fell due to the failure to achieve statistical significance in trial results.

What is the deadline to register as a lead plaintiff?

The deadline to register as a lead plaintiff is October 6, 2025.

Is there a cost to participate in the Altimmune case?

There is no cost or obligation to participate in this case.

Last updated: Sep 4, 2025